On August 6, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral immunotherapy, in combination with nivolumab for adult patients with unresectable advanced cutaneous melanoma who progressed on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. The Center for Biologics Evaluation and Research (CBER) decision, published in an FDA news release, authorizes Replimune, Inc. to market the product under the accelerated approval pathway (21 U.S.C. 356(c)) based on objective response rate and duration of response, with confirmatory post-approval trial(s) required to verify clinical benefit.
For regulatory, pharmacovigilance, and medical affairs teams, the novelty is a CBER-authorized engineered herpes simplex virus type 1 (HSV-1) oncolytic therapy in a contested anti-PD-1 refractory melanoma setting, not a routine small-molecule label update. The authorization lands one week after a July 30, 2026 Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) meeting and follows Breakthrough Therapy and Priority Review designations.
What exactly did FDA authorize on August 6, 2026?
FDA authorized Tudriqev plus nivolumab for unresectable Stage IIIB, IIIC, or IV cutaneous melanoma in adults whose disease progressed after at least eight consecutive weeks of prior anti-PD-1-based therapy. Tudriqev is an HSV-1-based oncolytic viral therapy engineered to replicate in tumor cells, lyse them, and help restore an anti-tumor immune response when combined with nivolumab.
Efficacy supporting accelerated approval came from an open-label, multiregional, single-arm trial that enrolled 140 adults; 91 were evaluated for response. The objective response rate was 24%, with a median duration of response of 14.1 months. Continued approval may be contingent on verification of clinical benefit in confirmatory trial(s) that Replimune must conduct as a condition of accelerated approval.
Common adverse reactions in more than 10% of patients included fatigue, pyrexia, infections, chills, musculoskeletal pain, nausea, diarrhea, injection-site reaction, headache, cough, influenza-like illness, rash, vomiting, pruritus, arthralgia, constipation, decreased appetite, dizziness, dyspnea, hemorrhage, edema, and abdominal pain. Labeling flags risk of herpes transmission to close contacts, herpes infection or reactivation in the patient, and injection-procedure complications.
Who must act now, and what changes in day-to-day compliance?
Replimune and its commercialization partners must lock labeling, REMS-adjacent communication if applicable, pharmacovigilance case definitions for oncolytic HSV-1 products, and promotional claims to the accelerated-approval evidence base (ORR and duration of response only until confirmatory benefit is verified). Oncology and gene-therapy sponsors watching CBER oncolytic and engineered-virus precedents should update internal pathway trackers: this file moved through CTGTAC on July 30, 2026, then to accelerated approval on August 6, 2026, under Breakthrough Therapy and Priority Review.
Hospital and clinic compliance teams administering intratumoral biologics need site SOPs for viral shedding precautions, contact counseling, and injection-procedure risk management from first commercial use. Continuous, per-jurisdiction real-time monitoring surfaces this class of CBER authorization the moment the agency publishes it, so RA calendars do not depend on ad hoc press scans.
What are the dosing and operational constraints for clinical use?
Tudriqev is injected directly into tumors once every two weeks for eight consecutive doses, with dose volume tied to tumor size. The first dose uses a lower concentration; subsequent doses use a higher concentration. Nivolumab is given intravenously beginning at week three of Tudriqev treatment. Those parameters drive pharmacy compounding controls, scheduling, and combination-therapy documentation from day one of launch.
| Element | Detail |
|---|---|
| Decision date | August 6, 2026 (FDA accelerated approval) |
| Advisory committee | CTGTAC, July 30, 2026 |
| Indication | Adult unresectable advanced cutaneous melanoma, anti-PD-1 refractory, with nivolumab |
| Primary evidence | Single-arm trial: 140 enrolled, 91 evaluated; ORR 24%; median DOR 14.1 months |
| Pathway conditions | Accelerated approval; confirmatory post-approval trial(s) required |
| Sponsor | Replimune, Inc. |
What should RA, PV, and medical affairs do before confirmatory data land?
Map the approved indication and exclusion criteria into labeling, medical information, and investigator communications so claims stay inside the accelerated-approval evidence package. Stand up PV signal detection for herpes transmission, reactivation, and injection-site complications, and align case narratives with the FDA safety list in the August 6, 2026 release.
Track confirmatory trial enrollment and readout timelines that will determine whether accelerated approval converts, is revised, or is withdrawn. Gene and oncolytic therapy peers should file the CTGTAC vote context and Breakthrough/Priority designations as precedent for future engineered-virus BLAs, without treating this as a horizontal industry rule change.
Take advantage of this real-time watch
Next steps: confirm whether any marketed or late-stage program in your portfolio sits in the same anti-PD-1 refractory melanoma or oncolytic HSV-1 class; update US biologics approval trackers for Tudriqev and Replimune post-marketing commitments; brief PV and medical affairs on the dosing schedule and herpes-related warnings; and watch confirmatory trial milestones that will decide continued approval. Obsidian keeps CBER authorizations like this visible as soon as they publish, so teams can act on the same day rather than after trade-press lag.
